Cephalosporins Should Be the Preferred Oral Antibiotics for Empiric Treatment of Outpatient Acute Pyelonephritis
When treating suspected outpatient pyelonephritis, consider switching your empiric oral choice to a cephalosporin unless local resistance patterns strongly dictate otherwise. While fluoroquinolones and TMP-SMX remain options, the push toward cephalosporins simplifies stewardship efforts without compromising coverage for most common pathogens. Always confirm susceptibility data if possible, as empirical choice should balance efficacy with minimizing collateral damage.
This article addresses the ongoing challenge of selecting optimal empiric oral antibiotics for managing acute pyelonephritis in the outpatient setting, a common and potentially serious ED encounter. While current practice often defaults to fluoroquinolones or TMP-SMX based on historical consensus guidelines, this review strongly advocates for cephalosporins as the preferred first-line oral agent. The core argument centers on improving antimicrobial stewardship while maintaining efficacy against uropathogens, thereby reducing the reliance on agents associated with increased resistance concerns or adverse effects. Choosing the right antibiotic is critical here to prevent progression to sepsis or nephrotoxicity.